Matisse Pharmaceuticals Receives FDA IND Clearance for Novel Sepsis Treatment Isupartob Sodium
Key Insights
Matisse Pharmaceuticals (search) received FDA IND clearance for isupartob sodium (search), enabling Phase II clinical trials for sepsis (search) treatment after completing two successful Phase I studies.
The novel therapeutic targets extracellular histones (search), key mediators of inflammation (search) and organ failure (search) in sepsis (search), representing a potentially breakthrough mechanism of action.
Sepsis (search) affects approximately 49 million people worldwide annually with 11 million deaths, representing a significant unmet medical need with no currently approved targeted therapies.
Matisse Pharmaceuticals (search) B.V. announced that the U.S. Food and Drug Administration has cleared the company's Investigational New Drug application for isupartob sodium (search), its lead compound for sepsis (search) treatment. The clearance enables the initiation of a Phase II clinical trial in patients with sepsis, marking a significant advancement for the Netherlands-based clinical stage company.
"IND clearance represents a key development milestone for the company. It advances its lead program into mid-stage clinical development," said Marcel Jacobs, CEO of Matisse Pharmaceuticals (search). The company has successfully completed two Phase I studies, including one in sepsis (search) patients, positioning it to evaluate the broader clinical potential of isupartob sodium (search) in Phase II trials.
Addressing Critical Unmet Medical Need
Sepsis (search) remains one of the most significant unmet medical needs in critical care medicine. The condition affects approximately 49 million people worldwide each year and causes an estimated 11 million deaths annually. Despite decades of research, no targeted therapies have been successfully developed to address the dysregulated host response that drives organ failure (search) and death in sepsis.
According to the WHO, sepsis (search) is one of the leading causes of death worldwide, with currently no effective treatment approved by regulatory authorities. More than 20% of the 49 million patients globally suffering from sepsis die each year. Approximately 40% of sepsis cases are children under the age of 5, with close to 3 million children dying from sepsis annually. According to a study by Buchman et al. (2020) published in Critical Care Medicine, sepsis is the most common cause of in-hospital deaths, costing over $62 billion annually in the USA alone.
Novel Mechanism Targeting Extracellular Histones
Isupartob sodium (search) represents a novel therapeutic approach designed to neutralize extracellular histones (search), which are key mediators of endothelial injury, inflammation (search) and organ failure (search) in sepsis (search). By targeting this upstream mechanism in the inflammatory cascade, the therapy aims to reduce mortality and improve outcomes in critically ill patients.
The drug is based on a specific discovery that in sepsis (search) patients, the innate immune system releases proteins known as histones into the bloodstream. These histones are toxic to cell membranes, leading to cell death and release of additional histones. The result is a self-enforcing cascade that drives organ failure (search). The highly negatively charged isupartob binds to these positively charged extracellular histones (search), thereby inhibiting the self-enforcing cascade with the ultimate goal to prevent further organ damage and death.
"Advancing isupartob sodium (search) into Phase II represents an important step in validating extracellular histone neutralization as a therapeutic strategy," said Kees Groen, Chief Development Officer of Matisse Pharmaceuticals (search). "We believe this mechanism may address a central driver of inflammation (search) and organ damage in sepsis (search) and potentially other inflammatory conditions."
Company Background
Matisse Pharmaceuticals (search) B.V. was founded in 2014 in Geleen, the Netherlands. The company develops safe and innovative therapies for disease indications characterized by elevated levels of circulating cytotoxic histones, including sepsis (search). The company's focus on histone neutralization represents a unique approach in the sepsis treatment landscape, where traditional therapies have largely failed to demonstrate significant clinical benefit.